GGrantIndex
← Search

Phase I safety &feasibility of immunotherapy in metastatic prostate carcinoma

$0M01FY2000RRNIH

Duke University, Durham NC

Investigators

Linked publications, trials & patents

View original record on NIH RePORTER →